Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Lilly’s new approach to cholesterol. Eli Lilly’s experimental cholesterol drug doubled patients’ HDL (Opens in a new window), or good cholesterol, setting the stage for a race between the ...

Eli Lilly and Co. LLY fell 18% in May, its steepest monthly drop since February 2009. ... UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% higher the next 12 months.

A cautious culture cost Novo its obesity lead. Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly.